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Abstract
Vandetanib	and	pazopanib	are	clinically	available,	multi-	targeted	inhibitors	of	vascu-
lar	endothelial	growth	factor	(VEGF)	and	platelet-	derived	growth	factor	(PDGF)	re-
ceptor	 tyrosine	 kinases.	 Short-	term	 VEGF	 receptor	 inhibition	 is	 associated	 with	
hypertension	in	15%-	60%	of	patients,	which	may	limit	the	use	of	these	anticancer	
therapies	over	the	longer	term.	To	evaluate	the	longer-	term	cardiovascular	implica-
tions	of	treatment,	we	investigated	the	“on”-	treatment	(21	days)	and	“off”-	treatment	
(10	days)	effects	following	daily	administration	of	vandetanib,	pazopanib,	or	vehicle,	
in	conscious	rats.	Cardiovascular	variables	were	monitored	in	unrestrained	Sprague-	
Dawley	 rats	 instrumented	with	 radiotelemetric	devices.	 In	Study	1,	 rats	were	 ran-
domly assigned to receive either daily intraperitoneal injections of vehicle (volume 
0.5	mL;	n	=	5)	or	vandetanib	25	mg/kg/day	(volume	0.5	mL;	n	=	6).	 In	Study	2,	rats	
received	either	vehicle	 (volume	0.5	mL;	n	=	4)	or	pazopanib	30	mg/kg/day	 (volume	
0.5	mL;	n	=	7),	dosed	once	every	24	hours	for	21	days.	All	solutions	were	in	2%	Tween,	
5% propylene glycol in 0.9% saline solution. Vandetanib caused sustained increases 
in	mean	arterial	pressure	 (MAP),	 systolic	blood	pressure	 (SBP),	and	diastolic	blood	
pressure	 (DBP)	compared	 to	baseline	and	vehicle.	Vandetanib	also	significantly	al-
tered	the	circadian	cycling	of	MAP,	SBP,	and	DBP.	Elevations	in	SBP	were	detectable	
162	hours	after	the	last	dose	of	vandetanib.	Pazopanib	also	caused	increases	in	MAP,	
SBP,	and	DBP.	However,	 compared	 to	vandetanib,	 these	 increases	were	of	 slower	
onset and a smaller magnitude. These data suggest that the cardiovascular conse-
quences	of	vandetanib	and	pazopanib	treatment	are	sustained,	even	after	prolonged	
cessation of drug treatment.
K E Y W O R D S
cardiovascular	pharmacology,	hypertension,	pazopanib,	radiotelemetry,	receptor	tyrosine	
kinase	inhibitors,	vandetanib
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1  | INTRODUC TION
One of the most potent mediators of angiogenesis is vascular endo-
thelial	growth	factor	(VEGF).1,2	The	VEGF	family	of	dimeric	polypep-
tide	ligands	includes	VEGF-	A,	VEGF-	B,	VEGF-	C,	VEGF-	D,	placental	
growth	 factor	 (PlGF),	 the	 virus-	encoded	 VEGF-	E,	 and	 the	 snake	
venom-	derived	 VEGF-	F.2	 VEGF-	A	 has	 been	 identified	 as	 the	 key	
regulator	of	angiogenesis,	a	process	critical	for	tumor	progression.3,4 
As	a	 result,	 several	antiangiogenic	 therapeutics	aimed	at	 targeting	
VEGF,	or	its	receptors,	have	emerged	as	key	adjuvant	cancer	treat-
ments	in	the	prolongation	of	progression-	free	survival	and,	in	some	
cases,	overall	survival.1
A	 number	 of	 receptor	 tyrosine	 kinase	 inhibitors	 (RTKIs)	 that	
target	VEGFR2	5,6 are now routinely used in the treatment of ad-
vanced	stage,	or	metastatic	disease.1,6,7 Vandetanib (Caprelsa®)	and	
pazopanib (Votrient®)	 are	 used	 to	 treat	 medullary	 thyroid	 cancer	
and	 advanced	 renal	 cell	 carcinoma,	 respectively.8,9	 Furthermore,	
sunitinib (Sutent®)	is	used	for	the	treatment	of	renal	cell	carcinoma,	
gastrointestinal stromal tumors and pancreatic neuroendocrine tu-
mors,	while	 sorafenib	 (Nexavar	®)	 is	 indicated	 for	 late-	stage	 treat-
ment of hepatocellular carcinoma or advanced metastatic renal cell 
carcinoma.10,11
RTKIs	 that	 inhibit	 VEGFR2	 tyrosine	 kinase	 activity	 effec-
tively	 reduce	 angiogenesis,	 potentially	 by	 decreasing	 the	 num-
ber of vessel nodes and vessel length in a tumor.1,4,7	Over	 time,	
this	 induces	 a	 hypoxic	 environment	within	 the	 tumor	 that	 leads	
to tumor cell death and a reduction in tumor size.12 Since these 
anticancer therapies target the tumor microvascular environ-
ment,	 it	 is	 perhaps	 not	 surprising	 that	 significant	 cardiovascular	
side	effects	have	been	reported,	both	clinically	and	in	preclinical	
studies.13,14	For	example,	in	patients	treated	with	bevacizumab,	a	
humanized	monoclonal	antibody	that	 targets	the	VEGF-	A	 ligand,	
28%	 of	 patients	 developed	 Grade	 3	 hypertension	 (>180	mm	Hg	
systolic	pressure).15 This pressor effect is also observed with small 
molecules	 that	 inhibit	 VEGFR2	 signaling.15	 Thus,	 15%-	60%	 of	
patients	 treated	with	 small	 molecule	 RTKIs	 have	 been	 reported	
to be associated with an increased incidence of hypertension.16 
Furthermore,	 the	escalation	of	hypertension	 in	 these	patients	 is	
linked with severe cardiovascular complications such as thrombo-
embolism,	 intracerebral	 hemorrhage,	 stroke,	 and	 myocardial	 in-
farction,	often	resulting	in	termination	of	treatment.13 Vandetanib 
has	been	shown	to	cause	ECG	prolongation,	and	hypertension	in	
over	32%	of	patients,	with	9%	of	 those	 treated	with	vandetanib	
developing	Grade	3	hypertension.17	Similarly,	hypertension	occurs	
in	 approximately	 40%-	57%	 of	 patients	 treated	 with	 pazopanib,	
with	3%	of	those	developing	Grade	3	hypertension.18,19	For	most	
patients,	 the	 onset	 of	 hypertension	 occurs	 within	 4	weeks	 of	
treatment.18,19
We recently recapitulated the hypertensive effects of a number 
of	RTKIs	 that	 target	VEGFR25 in a conscious rat model20 in which 
the	 regional	 hemodynamic	 effects	 of	 four	 RTKIs	 (including	 pazo-
panib	and	vandetanib)	were	monitored	over	a	period	of	4	days.	This	
study	showed	that	RTKIs	consistently	caused	hypertension,	which	
was	associated	with	regionally	selective	vasoconstrictions,	particu-
larly	in	the	hindquarters	and	mesenteric	vascular	beds.20	Short-	term	
radiotelemetric	 studies	 in	 rats	 have	 also	 examined	 the	 effects	 of	
RTKIs	on	blood	pressure	and	heart	rate	(HR).	Isobe	et	al21 dosed an-
imals	over	four	consecutive	days	with	vehicle,	cediranib	(0.1-	10	mg/
kg),	sunitinib	(0.5-	40	mg/kg),	or	sorafenib	(0.1-	5	mg/kg).21 The study 
clearly demonstrated significantly elevated blood pressures within a 
few	days	of	the	initiation	of	dosing	with	RTKIs.	Similarly,	Lankhorst	
et al22	showed	a	dose-	dependent	elevation	in	mean	arterial	pressure	
(MAP)	 following	administration	of	 sunitinib	 (7-	26.7	mg/day)	over	 a	
period of 5 days.22	More	recently	Collins	et	al23 evaluated more se-
lected	kinase	inhibitors	with	VEGFR-	2	activity,	AZ1,	and	regorafenib,	
again showing pressor effects when treatment was continued over 
a period of 4 days.23
In	 the	present	study,	we	have	used	 radiotelemetry	 to	evaluate	
the	 longer-	term	 impact	 of	 prolonged	 RTKI	 treatment	 on	 the	 car-
diovascular	system,	with	particular	attention	given	to	the	extent	to	
which	hypertension	is	sustained,	both	during	and	after	cessation	of	
treatment.	To	this	end,	we	have	evaluated	the	cardiovascular	effects	
of	two	clinically	available	RTKIs,	vandetanib,	and	pazopanib,	over	a	
21-	day	dosing	“on”-	period	and	during	a	10-	day	post	“off”-	treatment	
period,	in	freely	moving,	telemetered	rats.
2  | MATERIAL S AND METHODS
2.1 | Animals
Adult,	 male,	 Sprague-	Dawley	 rats	 (Charles	 River	 Laboratories,	
UK)	weighing	300-	400	g	were	housed	in	groups	in	a	temperature-	
controlled	 (21-	23°C)	environment	with	a	12	hours	 light–dark	cycle	
(lights	 on	 at	 06:00)	 and	 free	 access	 to	 food	 (18%	 Protein	 Rodent	
Diet;	Teklad	Global,	Bicester,	United	Kingdom)	and	water	ad	libitum.	
Following	 surgery,	 telemetered	 rats	were	 pair-housed	 in	 standard	
individually	ventilated	cages,	placed	upon	single	DSI	receivers,	with	
a noninstrumented companion rat throughout the duration of the 
study. Cages were prepared with bedding material and enrichment. 
All	 procedures	 were	 carried	 out	 with	 approval	 of	 the	 University	
of	Nottingham	Animal	Welfare	Ethical	Review	Board	under	Home	
Office	 Project	 and	 Personal	 License	 Authority.	 Every	 effort	 was	
made	 to	 ensure	 that	 animals	 experienced	 minimal	 discomfort.	
Twenty-	two	rats	were	used	for	this	study,	and	results	are	recorded	
in	accordance	with	the	ARRIVE	guidelines	for	reporting	experiments	
involving animals.24
2.2 | Surgical implantation of radiotelemetric devices
Surgery was performed under general anesthesia (fentanyl citrate 
and	medetomidine,	300	μg/kg	each,	i.p.,	supplemented	as	required).	
Sprague	Dawely	 rats	were	 implanted	with	 telemetry	 transmitters,	
DSI	 C50PXT	 (Study	 1:	 vandetanib),	 and	DSI	 HDS11	 (Study	 2:	 pa-
zopanib)	 (Data	Sciences	International,	St.	Paul,	MN	USA).	For	both	
devices,	 the	 catheter	 tip	 was	 advanced	 via	 the	 distal	 abdominal	
aorta	until	approximately	1	cm	below	the	renal	artery,	as	described	
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previously.25	 The	 positive	 ECG	 lead	 was	 secured	 to	 the	 xiphoid	
sternum	 and	 the	 negative	 ECG	 lead	 was	 placed	 over	 the	 manu-
brium and tunneled subcutaneously from the abdomen to the an-
terior of the neck.26 The telemetry device was secured to the body 
wall.	Following	surgery,	the	animals	received	reversal	of	anesthesia	
and postoperative analgesia provided by atipamezole hydrochlo-
ride	 (1	mg/kg,	s.c.)	and	buprenorphine	 (0.02	mg/kg,	s.c.).	A	second	
dose	of	buprenorphine	(0.02	mg/kg,	 i.p.)	was	given	as	an	analgesic	
4	hours	after	surgery	and	a	daily	dose	of	buprenorphine	(30	mg/kg,	
s.c.)	and	carprofen	(0.5%)	was	administered	for	4	days	postsurgery.	
The	animals	were	recovered	for	at	 least	10	days,	and	after	a	satis-
factory inspection from the Named Veterinary Surgeon the animals 
were	randomized	to	either	a	vehicle	or	treatment	group.	At	the	end	
of	each	experiment,	rats	were	euthanized	via	a	schedule	1	method,	
with	Euthatal	(60-	80	mg,	i.p.)	and	exsanguination.
2.3 | Telemetry
Following	 recovery	 from	 surgery,	 radiotelemetry	 devices	 were	
switched	on	and	baseline	 recordings	of	HR,	mean	systolic	blood	
pressure	 (SBP),	 mean	 diastolic	 blood	 pressure	 (DBP),	 and	 mean	
arterial	 blood	 pressure	 (MAP)	 were	 recorded	 every	 15	minutes	
for	 a	 period	 of	 1	min	 throughout	 the	 experimental	 period	 (ap-
proximately	35	days	 in	 total).	Baseline	recordings	were	collected	
for	a	minimum	of	4	days	prior	to	the	start	of	treatment.	After	this	
baseline	monitoring	period,	rats	were	randomly	assigned	into	two	
studies:
Study 1: Rats were randomly administered vehicle (volume 
0.5	mL;	n	=	5)	or	vandetanib	25	mg/kg/day	 (volume	0.5	mL;	n	=	6),	
dosed	i.p,	once	every	24	hours	for	21	days.	All	solutions	were	pre-
pared	in	(2%	Tween,	5%	propylene	glycol	in	0.9%	saline	solution).
Study 2:	 Animals	 were	 randomly	 assigned	 to	 receive	 vehicle	
(volume	0.5	mL;	n	=	4)	or	pazopanib	30	mg/kg/day	(volume	0.5	mL;	
n	=	7),	dosed	i.p,	once	every	24	hours	for	21	days.	All	solutions	were	
prepared	in	(2%	Tween,	5%	propylene	glycol	in	0.9%	saline	solution).
2.4 | Drugs, chemical reagents, and other materials
Pazopanib	and	vandetanib	were	purchased	from	Sequoia	Research	
Products,	 UK.	 Fentanyl	 citrate	 was	 purchased	 from	 Jansen-	Cilac	
Ltd,	UK.	Medetomidine	(Domitor),	carprofen	(Rimadyl)	and	atipam-
ezole	 hydrochloride	 (Antisedan)	 were	 purchased	 from	 Pfizer,	 UK.	
Buprenorphine	(Vetergesic)	and	pentobarbitone	(Euthatal)	were	pur-
chased	from	Alstoe	Animal	Health,	UK.	Tween	and	propylene	glycol	
were	purchased	from	Sigma-	Aldrich,	UK.
2.5 | Data analysis
Twenty-	four	hours	(00:00-	23:45),	morning	(06:00-	12:00)	and	even-
ing	(18:00-	23:45)	recording	averages	(means)	were	calculated	to	give	
HR,	MAP,	SBP,	and	DBP	values.	Change	from	baseline	calculations	
(time	point	-	average	of	the	baseline	=	change	from	baseline)	were	
used to determine ΔHR,	ΔMAP,	ΔSBP,	and	ΔDBP.
To	 evaluate	 vandetanib-	 or	 pazopanib-	induced	 changes	 in	 cir-
cadian cycling during initial 2 days of dosing and the last 2 days of 
dosing	 followed	by	 the	10-	day	postdosing	period	with	vandetanib	
and	pazopanib,	each	24	hours	day	was	divided	into	6,	3	hours	bins	
(06:00-	09:00,	 09:00-	12:00,	 12:00-	15:00,	 15:00-	18:00,	 18:00-	
21:00,	and	21:00-	24:00)	and	HR,	MAP,	SBP,	and	DBP	were	calcu-
lated	for:	(1)	the	last	2	days	of	baseline	(pre-treatment)	and	the	first	
3	days	of	dosing	with	either	 vandetanib,	pazopanib,	or	 vehicle;	 (2)	
days	20	and	21	of	dosing	with	vandetanib,	pazopanib,	or	vehicle,	fol-
lowed	by	the	10-	day	“off”-	treatment	period	(days	22-	31).
All	 data	 were	 expressed	 as	 mean	±	SEM.	 Data	 were	 analyzed	
using	Prism	6	software	(GraphPad	software,	USA).	Differences	were	
considered significant if the P-	value	was	 less	 than	0.05.	To	assess	
statistical differences between vehicle or treatment groups (van-
detanib	 or	 pazopanib),	 two-	tailed	 comparisons	 of	 the	 integrated	
area	under	 the	curve	were	made	using	 the	Mann-	Whitney-	U	 test.	
A	 repeated	measures	ANOVA	with	Sidak's	correction	was	used	 to	
compare	drug	treatment	 to	vehicle	at	 individual	 time	points.	A	re-
peated	measures	nonparametric	ANOVA	with	Dunnet's	correction	
was used to compare each time point to the baseline average.
3  | RESULTS
In	 the	 present	 study,	 we	 investigated	 hemodynamic	 responses	 to	
vandetanib	(25	mg/kg/day,	i.p.)	or	pazopanib	(30	mg/kg/day,	i.p.)	in	
conscious	telemetered	rats	following	chronic	treatment,	over	a	21-	
day	dosing	period	and	a	10-	day	“off”-	treatment	period.	The	circadian	
rhythm,	oscillating	cycles	of	cardiovascular	variables	over	a	24	hours	
time	period,	were	also	measured	during	the	last	2	days	of	baseline	
followed	by	 the	 first	3	days	of	dosing	with	vandetanib,	pazopanib,	
or	 vehicle	 and	 the	 last	 2	days	 of	 dosing	 followed	 by	 the	 10-	day	
posttreatment period. This was to investigate whether vandetanib 
or pazopanib interfered with the natural cycling of hemodynamic 
processes	over	a	24	hours	period	and	over	multiple	days.	Baseline	
cardiovascular	 variables	 before	 the	 administration	 of	 RTKI	 or	 the	
corresponding vehicle are shown in Table 1.
3.1 | Cardiovascular effects of Vandetanib
3.1.1 | Heart rate
A	single,	daily	dose	of	vandetanib	 for	21	days	did	not	significantly	
alter	 HR	 compared	 to	 baseline	 at	 any	 time	 point	 during	 either	
the	 dosing	 period	 or	 the	 “off”-	treatment	 period	 (Figure	 S1a,c,e).	
Vandetanib	 did,	 however,	 significantly	 decrease	 the	 change	 in	HR	
(ΔHR;	 relative	 to	 the	 corresponding	 initial	 baseline	 measurement	
obtained	for	each	animal)	on	the	4th	and	10th	day	of	dosing	and	the	
2nd,	6th,	 and	10th	day	of	 the	 “off”-	treatment	period	 (Figure	S1b).	
The majority of these ΔHR	decreases	appeared	during	the	animal's	
active	phase	 (21:00-	06:00)	 for	both	 the	dosing	and	the	posttreat-
ment	periods	 (Figure	S1d).	However,	declines	 in	HR	and	ΔHR	over	
time	were	also	found	with	vehicle	(Figures	S1a-	f)	suggesting	that	the	
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changes	in	HR	from	the	initial	baseline	measurements	were	probably	
not	entirely	due	 to	vandetanib.	This	 is	probably	a	consequence	of	
habituation to the dosing regimens and a reduction in sympathetic 
nervous system activity.
When	integrated	area	under	the	curve	analysis	was	undertaken,	
it identified significant differences between the vandetanib and ve-
hicle	groups	 for	 the	duration	of	 the	21-	day	dosing	period	and	 the	
10-	day	posttreatment	period	 (Mann-	Whitney	U	test,	#	=	P < 0.05; 
Figure	 S1d-	f).	 Vandetanib	 did	 not	 significantly	 alter	 the	 circadian	
rhythm	of	HR	compared	to	baseline	during	the	initial	3	days	of	dos-
ing	(Figure	1A)	or	the	last	2	days	of	dosing	followed	by	the	10-	day	
posttreatment	period	 (Figure	1B).	 Integrated	area	under	 the	curve	
analysis of these data detected significant differences between 
vehicle	 and	vandetanib	during	 the	 initial	 3	days	of	 dosing	 and	 the	
10-	day	posttreatment	period	(Figures	1A-	B).	Thus,	the	peak-	trough	
amplitude	of	the	circadian	rhythm	in	HR	decreased	during	the	first	
3	days	of	treatment	with	vandetanib	(Figure	1A)	and	then	recovered	
during	 the	 “off”-	treatment	period	 (Figure	1B).	Bradycardic	 tenden-
cies	were	also	observed	during	the	days	1-	5	and	5-	10	averages,	of	
the	“off”-	treatment	period	(Table	S1).
3.1.2 | Blood pressure
Significant pressor effects of vandetanib (P	<	0.05)	were	observed	
on	 both	 MAP	 (Figure	2A,C,E)	 and	 the	 change	 in	 MAP	 from	 the	
original baseline measurement of each individual animal (ΔMAP)	
(Figure	2B,D,F).	There	was	a	significant	increase	in	ΔMAP	compared	
to baseline from the first active evening phase of vandetanib dos-
ing	and	this	elevation	remained	throughout	the	21-	day	dosing	period	
and	6	days	into	the	“off”-	treatment	period	(Figure	2B,D,F).	The	maxi-
mum response was achieved on the 20th day of treatment (24 hours 
measurement;	 vandetanib	=	+13	±	2	mm	 Hg,	 vehicle	=	+1	±	1	mm	
Hg,	P	<	0.05;	Figure	2A).	Over	the	24	hours	recording	period,	ΔMAP	
appeared	to	have	a	sustained	component	during	the	“off”-	treatment	
period	 (Figure	2B).	 This	was	 particularly	 apparent	 during	 the	 rest-
ing	 morning	 recordings	 (06:00-	12:00)	 (Figure	2D).	 Consistent	 and	
significant	differences	in	both	MAP	and	ΔMAP	were	observed	be-
tween	vehicle	and	vandetanib	throughout	the	21-	day	dosing	period	
and	during	the	10-	day	“off”-	treatment	period	(Mann-	Whitney	U	test,	
P	<	0.05;	Figure	2A-	F).	MAP	elevations	were	also	sustained	through-
out	 the	 10-	day	 “off”-	treatment	 period,	 and	 this	 was	 significant	
compared	 to	 vehicle,	 during	 days	 1-	5	 and	 5-	10	 (Table	 S1).	 There	
was	no	evidence	of	tolerance	to	the	effects	of	vandetanib,	at	least	
in	terms	of	blood	pressure	responses,	during	the	21-	day	treatment	
period	(Figure	2A-	F).
Vandetanib significantly (P	<	0.05)	increased	SBP	and	the	change	
in	SBP	from	baseline	(ΔSBP)	from	the	second	day	of	dosing	(Figure	3A-	
F).	Vandetanib	caused	significant	increases	in	ΔSBP	compared	to	ve-
hicle and this elevation appeared to be of a larger magnitude during 
the	morning	 resting	 phase	 (Figure	3D).	 Significant	 increases	 in	 SBP	
were also found with vandetanib treatment compared to vehicle 
for	 the	entire	10-	day	 “off”-	treatment	period	 (Figure	3A-	F;	Table	S1).	
Vandetanib	 induced	 smaller	 increases	 in	 mean	 DBP	 and	 change	 in	
F IGURE  1 Circadian oscillations of the mean heart rate 
(HR)	of	rats	dosed	with	vandetanib	25	mg/kg/day	(n	=	6)	and	
vehicle	(n	=	5).	During:	(A)	2	days	prior	to	dosing	followed	by	
the	first	3	days	of	dosing;	and	(B)	the	last	2	days	of	the	dosing	
period	followed	by	10	days	“off-	treatment”.	Data	are	displayed	
as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; 
+P < 0.05 comparing vehicle vs vandetanib at the same time point 
and #P < 0.05 comparing area over or under the curve of vehicle vs 
vandetanib
HR (beats/min) MAP (mm Hg) SBP (mm Hg) DBP (mm Hg)
Series 1 baseline values
Vehicle	1	(n	=	5) 395	±	2 108	±	0 128	±	0 92	±	0
Vandetanib 25 mg/kg/
day	(n	=	6)
373	±	4* 108	±	0 128	±	0 92	±	1
Series 2 baseline values
Vehicle	2	(n	=	4) 370	±	5 101	±	0 124	±	0 83	±	0
Pazopanib	30	mg/kg/
day	(n	=	7)
372	±	4 99	±	0 120	±	0* 82	±	0
TABLE  1 Baseline	cardiovascular	
variables	for	heart	rate	(HR),	mean	arterial	
pressure	(MAP),	systolic	blood	pressure	
(SBP),	and	DBP	(24	h).	Statistics:	*P < 0.05; 
Comparing vehicle and vandetanib groups 
or vehicle and pazopanib groups. Values 
have been rounded to the nearest whole 
number
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DBP	from	baseline	(ΔDBP)	that	is	probably	not	physiologically	relevant	
(Figure	4A-	F;	Table	S1).
Circadian	 rhythm	 observations	 revealed	 that	 MAP,	 SBP,	 and	
DBP	levels	peaked	during	rodent	active	evening	phase	and	reached	
lower levels during the rodent resting phase throughout the base-
line and posttreatment periods. During the vandetanib dosing pe-
riod,	 these	 oscillations	were	 disturbed	 and	 clear	 elevations	 in	 all	
three	pressure	 responses	were	observed	 (Figure	5A-	F).	 This	 con-
trasted with the better maintained circadian rhythm observed in 
HR	(Figure	1A-	B).
3.2 | Cardiovascular effects of Pazopanib
3.2.1 | Heart rate
Pazopanib	did	not	significantly	alter	HR	compared	to	baseline	(Figure	
S2a,c,e).	As	observed	with	vandetanib	above,	ΔHR	was	reduced	over	
time in both the pazopanib and vehicle groups compared to baseline. 
This was particularly evident during the resting morning phase and 
this	 decrease	 was	 sustained	 throughout	 the	 10-	day	 posttreatment	
period	(Figure	S2d).	Pazopanib	did	not	significantly	alter	HR	or	ΔHR	
F IGURE  2 Mean	arterial	blood	pressure	(MAP)	of	rats	dosed	with	vandetanib	25	mg/kg/day	(n	=	6)	and	vehicle	(n	=	5).	A,	MAP	and	B,	
change	in	MAP	compared	to	baseline	(ΔMAP)	measured	for	24	hours;	C,	MAP	and	D,	ΔMAP	measured	during	the	morning	(06:00-	12:00);	E,	
MAP	and	F,	ΔMAP	measured	during	the	evening	(18:00-	23:45).	Data	are	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to 
baseline; +P < 0.05 comparing vehicle vs vandetanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle 
vs vandetanib
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compared	to	vehicle	at	any	particular	time	point	measured.	However,	
integrated area under the curve analysis revealed significant trend dif-
ferences	between	pazopanib	and	vehicle	during	the	24	hours,	morning	
and evening measurements of ΔHR	(Mann-	Whitney	U	test,	P < 0.05; 
Figure	S2b,d,f).
The	HR	circadian	oscillations	measured	during	pazopanib	dosing	
did	 not	 differ	 from	vehicle	 or	 baseline	 for	 first	 3	days	 of	 treatment	
(Figure	S3a).	However,	during	the	9th	and	10th	day	of	the	posttreat-
ment period significant tachycardia was found compared to vehicle 
(Figure	S3b).	 Integrated	area	under	the	curve	analysis	also	identified	
significant trend differences between pazopanib and vehicle through-
out	 the	 last	 2	days	 of	 dosing	 and	 the	 10-	day	 posttreatment	 period	
(Mann-	Whitney	U	test,	P	<	0.05;	Figure	S3B).	This	suggests	that	HR	
increases associated with pazopanib only occur post dosing.
3.2.2 | Blood pressure
Similar	to	vandetanib,	21	days	of	pazopanib	dosing	caused	significant	
pressor	 effects,	when	 observing	ΔMAP,	 compared	 to	 the	 starting	
baseline	values	(Figure	6).	However,	these	effects	were	not	detected	
by	MAP	raw	data	 (Figure	6A,C,E).	Additionally,	when	compared	 to	
vandetanib	treatment,	the	effects	of	pazopanib	were	slower	in	onset	
and	 of	 smaller	 magnitude	 (Figure	6B,D,F).	 Pazopanib	 induced	 sig-
nificant increases in ΔMAP	from	the	third	day	of	pazopanib	dosing,	
F IGURE  3 Mean	systolic	pressure	(SBP)	of	rats	dosed	with	vandetanib	25	mg/kg/day	(n	=	6)	and	vehicle	(n	=	5).	A,	SBP	and	B,	change	
in	SBP	compared	to	baseline	(ΔSBP)	measured	for	24	hours;	C,	SBP	and	D,	ΔSBP	measured	during	the	morning	(06:00-	12:00);	E,	SBP	
and	F,	ΔSBP	during	the	evening	(18:00-	23:45).	Data	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; +P < 0.05 
comparing vehicle vs vandetanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle vs vandetanib
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taking	 2	days	 longer	 to	 peak	 compared	 to	 the	 vandetanib-	treated	
animals	(Figure	6B,D,F	vs	Figure	2B,D,F).	This	persisted	until	the	end	
of	the	experiment	(Figure	6B).	The	effects	of	pazopanib	on	MAP	dur-
ing the rodent resting morning phase were variable and somewhat 
inconsistent	(Figure	6D).	However,	during	the	active	evening	period,	
elevation in ΔMAP	was	more	consistent	and	sustained	throughout	
both	 the	 treatment	 period	 (21	days)	 and	 “off”-	treatment	 period	
(10	days)	(Figure	6B,D,F).
Pazopanib	 significantly	 increased	 ΔSBP	 during	 the	 24	hours	
and	 the	 active	 evening	 measurements	 (Figure	7).	 This	 was	 sus-
tained	 throughout	 both	 the	 21-	day	 dosing	 period	 and	 the	 10-	day	
“off”-	treatment	 period	 (P	<	0.05;	 Figure	7B,F).	 However,	 raw	 SBP	
data	did	not	show	pazopanib	induced	changes	(Figure	7A,C,E;	Table	
S2).	 In	addition,	unlike	vandetanib	 treatment,	no	changes	 in	ΔSBP	
were observed in the morning resting phase with pazopanib treat-
ment,	compared	to	baseline.	During	the	active	evening	phase,	there	
were significant differences between pazopanib and vehicle groups 
on	the	11th	and	15th	day	of	the	dosing	period	and	the	8th	day	of	
the	posttreatment	period	(Figure	7F).	 Interestingly,	 integrated	area	
under the curve analysis found trend differences in ΔSBP	 found	
between	vehicle	and	pazopanib	over	 the	entire	experiment,	 in	 the	
24	hours,	 morning	 and	 evening	 (Mann-	Whitney	 U	 test,	 P < 0.05; 
F IGURE  4 Mean	diastolic	pressure	(DBP)	of	rats	dosed	with	vandetanib	25	mg/kg/day	(n	=	6)	and	vehicle	(n	=	5).	A,	DBP	and	B,	change	
in	DBP	compared	to	baseline	(ΔDBP)	measured	for	24	h;	C,	DBP	and	D,	ΔDBP	measured	during	the	morning	(06:00-	12:00);	E,	DBP	and	F,	
ΔDBP	measured	during	the	evening	(18:00-	23:45).	Data	are	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; 
+P < 0.05 comparing vehicle vs vandetanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle vs 
vandetanib
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Figure	7B,D,F).	 Similar	 effects	 were	 observed	 on	 DBP	 and	ΔDBP	
(Figure	8).
In	 contrast	 to	 vandetanib,	 pazopanib	did	not	 significantly	 alter	
the	 circadian	pattern	of	MAP,	SBP,	or	DBP	during	 the	 first	3	days	
of pazopanib dosing or the last 2 days of pazopanib dosing followed 
by	a	10-	day	“off”-	treatment	period,	compared	to	vehicle	or	baseline	
(Figure	S3c-	h).
4  | DISCUSSION
In	 the	 present	 study,	 we	 have	 demonstrated	 that,	 in	 rats	 instru-
mented for radiotelemetry recording of blood pressure and other 
cardiovascular	 variables	 over	 an	 extended	 period,	 hypertension	
can be induced by both vandetanib and pazopanib. These findings 
extend	previous	telemetry-	based	studies	in	rats	using	related	RTKI	
treatments.21-23,27,28 They are also consistent with the hypertensive 
effects of vandetanib and pazopanib that have been described in 
the clinical setting18;	Pinkas	et	al,	2017).	Of	particular	note	 in	 this	
study,	 however,	 is	 the	 finding	 that	 after	 extended	 treatment	with	
both	RTKIs,	which	more	closely	reflects	the	clinical	regimens,	blood	
pressure	 remained	consistently	elevated,	even	after	8-	10	days	 fol-
lowing	 the	 cessation	of	 treatment.	 In	 the	 case	of	 vandetanib,	 this	
time	 scale	 is	 entirely	 consistent	with	Phase	1	 clinical	 trials	 in	man	
that have indicated that this drug is eliminated slowly from the body 
with a t1/2 of circa 10 days.
29	Pazopanib	is	excreted	more	quickly	and	
the estimated t1/2 in man is circa	30	h	(Australian	Public	Assessment	
Report	PM-	2009-	01084-	4).
The effects of vandetanib were most obvious in terms of ele-
vation	in	SBP,	however,	there	was	also	an	elevation	in	DBP,	partic-
ularly	throughout	the	treatment	period.	Compared	to	vandetanib,	
the increase in blood pressure with pazopanib was slower in onset 
F IGURE  5 Circadian	oscillations	of:	(A-	B)	mean	arterial	pressure	(MAP),	(C-	D)	systolic	blood	pressure	(SBP),	and	(E-	F)	diastolic	blood	
pressure	(DBP)	in	rats	dosed	with	vandetanib	25	mg/kg/day	(n	=	6)	and	vehicle	(n	=	5).	Representing:	(A,	C,	E)	2	days	prior	to	dosing;	and	
the	first	3	days	of	dosing;	and	(B,	D,	F)	the	last	2	days	of	dosing	followed	by	10	days	“off-	treatment”.	Data	are	displayed	as	mean	±	SEM.	
*P < 0.05 comparing each time point to baseline; +P < 0.05 comparing vehicle vs vandetanib at the same time point and #P < 0.05 comparing 
area over or under the curve of vehicle vs vandetanib
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and smaller in magnitude. The elevation in overall pressure is con-
sistent	with	our	previous	studies	using	these	RTKIs	in	the	Doppler	
flowmetry	 model,	 wherein	 we	 showed	 significant	 increases	 in	
MAP	with	 both	 vandetanib	 and	 pazopanib	 that	were	 associated	
with	vasoconstrictions	in	the	mesenteric	and	hindquarters	vascu-
lar beds.20	While	DBP	was	not	directly	measured	in	these	earlier	
studies,	it	would	be	expected	that	changes	in	peripheral	vascular	
resistance	would	 strongly	 affect	 DBP.30	 In	 the	 present	 study,	 it	
would	 appear	 that	 these	 RTKIs	 have	 directly	 affected	 SBP	 to	 a	
greater	extent	than	DBP,	likely	via	mechanisms	involving	changes	
in	 stroke	 volume	 and	 contractility.	However,	 further	 studies	 are	
clearly	needed	to	better	understand	the	effects	of	RTKIs	on	DBP	
and	SBP.
It is notable that pazopanib is much more potent as an inhibitor 
of	 VEGFR2-	mediated	 signaling	 or	 binding	 than	 vandetanib.5,6 It is 
therefore	possible	that	other	kinases	(other	than	VEGFR2)	may	addi-
tionally	contribute	to	larger	effects	of	vandetanib	on	MAP	and	SBP	
observed	here.	These	might	include	RTKs	such	as	EGFR	and	PDGFR	
which have higher affinity for vandetanib.6
This	 study	 is	 the	 first	 to	 monitor	 the	 longer-	term,	 continuous	
impact of vandetanib and pazopanib on the cardiovascular system. 
Similar	 or	 related	 RTKIs	 such	 as	 cediranib,31	 sorafenib,20,21 and 
F IGURE  6 Mean	arterial	blood	pressure	(MAP)	of	rats	dosed	with	pazopanib	30	mg/kg/day	(n	=	7)	and	vehicle	(n	=	4).	A,	MAP	B,	change	
in	MAP	compared	to	baseline	(ΔMAP)	measured	for	24	hours,	C,	MAP	and	D,	ΔMAP	measured	during	the	morning	(06:00-	12:00),	E,	MAP	
and	F,	ΔMAP	measured	during	the	evening	(18:00-	23:45).	Data	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; 
+P < 0.05 comparing vehicle vs pazopanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle vs 
pazopanib
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sunitinib28,32 have been investigated in other studies where the car-
diovascular effects of these compounds were monitored over pe-
riods	 of	 between	4	days	 and	4	weeks	 (continuous)	 treatment,	 and	
showed	 that	MAP	 returns	 quickly	 to	 baseline	 levels	 following	 the	
end	of	treatment.	Indeed,	Blasi	et	al32 noted that the pressor effects 
of sunitinib diminished even during the last few days of treatment. 
Moreover,	 no	 associated	 changes	 in	 cardiac	 structure	 or	 function	
were observed.32
Observation of the circadian changes in cardiovascular variables 
revealed	that	HR,	MAP,	SBP,	and	DBP	all	peaked	during	the	rodent	
active evening phase and reached lower levels during the rodent 
resting	phase.	During	the	vandetanib	dosing	period,	the	oscillations	
in	MAP,	 SBP,	 and	 DBP	 were	 disrupted	 and	 clear	 elevations	 in	 all	
three	pressure	 responses	were	observed.	However,	during	vande-
tanib	 treatment	 the	 circadian	 rhythm	 observed	 in	 HR	 was	 much	
better	maintained.	 In	contrast,	 following	pazopanib	 treatment,	 the	
periodic circadian variations in all four cardiovascular variables were 
well maintained. These changes point to multiple factors contribut-
ing to the larger and more disruptive changes in diurnal variations 
in	blood	pressure	observed	with	vandetanib	(relative	to	pazopanib).
Although	the	very	slow	elimination	and	clearance	of	vandetanib	
from the body29 is likely to contribute to the maintained increased 
in	blood	pressure	observed	in	the	present	study	during	the	10-	day	
“off”-	treatment	 period,	 it	 is	 also	 likely	 that	 other	 hemodynamic	
F IGURE  7 Mean	systolic	pressure	(SBP)	of	rats	dosed	with	pazopanib	30	mg/kg/day	(n	=	7)	and	vehicle	(n	=	4).	A,	SBP	and	B,	change	in	
SBP	compared	to	baseline	(ΔSBP)	measured	for	24	hours,	C,	SBP	and	D,	ΔSBP	measured	during	the	morning	(06:00-	12:00),	E,	SBP	and	F,	
ΔSBP	measured	during	the	evening	(18:00-	23:45).	Data	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; +P < 0.05 
comparing vehicle vs pazopanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle vs pazopanib
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compensatory mechanisms are contributing to this sustained effect. 
For	 example,	 the	 diurnal	 variation	 in	HR	 is	maintained	well	 in	 the	
presence	 of	 both	 drugs,	 although	 in	 the	 case	 of	 vandetanib,	 drug	
treatment	leads	to	a	small	bradycardia	and	a	reduction	in	the	peak-	
trough	amplitudes.	During	vandetanib	treatment,	however,	mainte-
nance	of	a	regular	diurnal	change	in,	particularly,	SBP	took	longer	to	
reestablish	after	the	 initial	pressure	response.	 It	 is	possible,	 there-
fore,	 that	 some	 resetting	of	 the	blood	pressure	occurs	during	 this	
period.	In	the	case	of	pazopanib,	there	are	parallel	changes	in	both	
DBP	(elevation)	and	HR	during	the	drug	washout	phase	that	might	
also	point	 to	 compensatory	 changes,	 particularly	 since	 these	both	
appear	to	result	from	an	extended	period	of	peak	blood	pressure	and	
HR	during	the	rodent	active	period.
The	 mechanisms	 underlying	 the	 hypertensive	 effects	 of	 anti-	
VEGF	therapies	has	yet	to	be	fully	elucidated,	although	a	reduction	
in	VEGF-	induced	nitric	oxide	(NO)	production	has	been	heavily	im-
plicated.33,34	Under	normal	physiological	conditions,	VEGF	signaling	
enhances	endothelial-	derived	NO	production;	 this	vasoactive	sub-
stance	is	subsequently	available	to	act	on	vascular	smooth	muscle,	
evoking a vasodilatation and reducing overall peripheral vascular re-
sistance.33	Interference	with	the	VEGF	signaling	cascade	decreases	
the	 availability	 of	 NO,	 and	 is	 associated	 with	 vasoconstriction,	
F IGURE  8 Mean	diastolic	pressure	(DBP)	of	rats	dosed	with	pazopanib	30	mg/kg/day	(n	=	7)	and	vehicle	(n	=	4).	(A)	DBP	and	(B)	change	
in	DBP	compared	to	baseline	(ΔDBP)	measured	for	24	hours,	(C)	DBP	and	(D)	ΔDBP	measured	during	the	morning	(06:00-	12:00),	(E)	DBP	
and	(F)	ΔDBP	measured	during	the	evening	(18:00-	23:45).	Data	displayed	as	mean	±	SEM.	*P < 0.05 comparing each time point to baseline; 
+P < 0.05 comparing vehicle vs pazopanib at the same time point and #P < 0.05 comparing area over or under the curve of vehicle vs 
pazopanib
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capillary	 rarefaction,	 and	consequently	hypertension.33,34	To	date,	
the	 pathophysiology	 of	 RTKI-	induced	 hypertension,	 particularly	
relating	to	inhibition	of	VEGF,	 is	poorly	defined.	There	is	some	ev-
idence to suggest that concomitant treatment with antihyperten-
sive	agents	 targeting	 the	 renin-	angiotensin-	aldosterone	system,	or	
calcium	signaling	pathways,	may	 improve	progression-	free	survival	
and overall survival in cancer patients (reviewed by reference.34 
Moreover,	in	vitro	data	suggest	that	nitrates	and	beta-	blockers	may	
also	be	associated	with	cancer	 regression.	However,	until	we	 fully	
understand the pathways and mechanisms underlying the cardiovas-
cular	effects	of	VEGF	which	are	essential	for	normal	function,	future	
developments in the therapeutic area will remain a challenge.
It	 is	widely	acknowledged	 that	VEGF	and	 its	 receptors	are	ex-
pressed in a variety of tissues under normal physiological condi-
tions.35-38	During	development,39,40 wound healing41 and the luteal 
phase	of	the	menstrual	cycle,42	VEGF	expression	is	high.	However,	
its	role	in	the	quiescent	vasculature	has	yet	to	be	fully	determined	
and	until	recently	it	was	believed	that	VEGF	played	an	insignificant	
role in the established adult vasculature.
However,	 there	 is	 increasing	 evidence	 demonstrating	 the	 im-
portant	role	of	VEGF	in	survival	of	not	only	angiogenic	vessels,	but	
normal,	 established	 vasculature	 as	 well.12,35,43,44	 Thus,	 prolonged	
anti-	VEGF	 therapy	 is	 associated	 with	 the	 concept	 of	 rarefaction,	
“normalisation”	of	the	vasculature43 and remodeling of these newly 
formed microvessels. This leads to a loss of structural pericyte cover-
age,	and	in	many	cases	actual	regression	of	the	blood	vessels.12,35,43 
More	 recently,	 it	has	also	been	suggested	 that	VEGF	plays	a	 simi-
lar	 role	 in	maintaining	 the	 function	of	normal	well-	established	mi-
crovessels.35	 If	 so,	 this	may	 explain	 the	 hypertension	 observed	 in	
patients	following	RTKI	treatment,	since	this	will	naturally	lead	to	an	
increase in overall total peripheral resistance.20,44 If this hyperten-
sion	is	indeed	based	on	structural	changes	in	the	vasculature,	then	
this could well contribute to the sustained hypertension observed in 
the	present	study	during	the	“off”-	drug	period,	particularly	following	
vandetanib treatment.
In	 summary,	 the	 present	 study	 has	 demonstrated	 that	 the	 hy-
pertension	 associated	 with	 RTKI	 treatment	 can	 be	 recapitulated	
in a conscious rat model and that this cardiovascular effect is sub-
stantially	 maintained	 during	 a	 prolonged	 “off”-	treatment	 period.	
The	reasons	for	this	remain	to	be	established,	but	further	work	on	
the potential changes in microvessel structure and the role of local 
vasoactive	substances	 (eg,	NO)	should	begin	 to	provide	 important	
insights into the mechanisms underlying this serious side effect. This 
is particularly relevant to the clinical situation where antiangiogenic 
adjunct	therapies	are	being	extended	from	patients	with	late-	stage	
cancer to younger patients at an earlier stage of disease progression.
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